Gilead Sciences (GILD) Reports Q2 EPS of $0.49
More News related to GILD
- Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
More News related to Earnings
- Copart (CPRT) Reports Q1 EPS of $0.42, Beats by 1c
- PDL BioPharma (PDLI) Reports Q4 Revenues
- Shanda Games (GAME) Reports Q3 Adj-EPS of $0.24
- American Technology (ATCO) Posts Q3 Loss of 3c, Misses Views; Revs Higher Y/Y
- American Technology (ATCO) Reports '09 Financials
Gilead Sciences (Nasdaq: GILD) reports Q2 EPS of $0.49, 1 cent better than the analyst estimate of $0.48. Revenues for the quarter were $1.28 billion, versus the consensus of $1.24 billion.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
